Structures by: Boldyreva E. V.
Total: 418
Glycine-DL-tartaric acid (1:1)
C4H6O6,C2H5NO2
CrystEngComm (2016) 18, 31 5869
a=4.8316(3)Å b=9.291(2)Å c=20.4354(15)Å
α=90° β=102.972(6)° γ=90°
Glycine-DL-tartaric acid (1:1)
C4H6O6,C2H5NO2
CrystEngComm (2016) 18, 31 5869
a=4.8193(3)Å b=9.2205(12)Å c=18.9807(13)Å
α=99.010(8)° β=93.373(6)° γ=96.474(8)°
Glycine-DL-tartaric acid (1:1)
C4H6O6,C2H5NO2
CrystEngComm (2016) 18, 31 5869
a=4.8011(3)Å b=9.1664(13)Å c=18.8557(16)Å
α=99.072(9)° β=93.873(6)° γ=96.313(8)°
Glycine-DL-tartaric acid (1:1)
C4H6O6,C2H5NO2
CrystEngComm (2016) 18, 31 5869
a=4.7793(3)Å b=9.0995(12)Å c=18.7215(16)Å
α=99.175(8)° β=94.392(6)° γ=96.158(8)°
Glycine-DL-tartaric acid (1:1)
C4H6O6,C2H5NO2
CrystEngComm (2016) 18, 31 5869
a=4.7548(3)Å b=9.0519(10)Å c=18.5909(11)Å
α=99.268(7)° β=94.920(5)° γ=95.865(7)°
Glycine-DL-tartaric acid (1:1)
C4H6O6,C2H5NO2
CrystEngComm (2016) 18, 31 5869
a=4.7294(3)Å b=9.0150(12)Å c=18.4226(14)Å
α=99.561(8)° β=95.475(6)° γ=94.927(8)°
Glycine-DL-tartaric acid (1:1)
C4H6O6,C2H5NO2
CrystEngComm (2016) 18, 31 5869
a=4.7136(3)Å b=8.9774(10)Å c=18.3305(11)Å
α=99.633(7)° β=95.811(5)° γ=94.695(6)°
Glycine-DL-tartaric acid (1:1)
C4H6O6,C2H5NO2
CrystEngComm (2016) 18, 31 5869
a=4.6911(3)Å b=8.9235(11)Å c=18.2045(11)Å
α=99.652(7)° β=96.245(5)° γ=94.537(7)°
Glycine-DL-tartaric acid (1:1)
C4H6O6,C2H5NO2
CrystEngComm (2016) 18, 31 5869
a=4.7036(3)Å b=8.9504(12)Å c=18.2696(14)Å
α=99.640(8)° β=96.012(6)° γ=94.585(8)°
Glycine-DL-tartaric acid (1:1)
C4H6O6,C2H5NO2
CrystEngComm (2016) 18, 31 5869
a=4.6691(3)Å b=8.8675(10)Å c=18.0795(11)Å
α=99.614(7)° β=96.706(5)° γ=94.481(7)°
Metacetamol, 3-Acetamidophenol
C8H9NO2
CrystEngComm (2015) 17, 32 6183
a=7.6202(8)Å b=19.010(3)Å c=10.1116(8)Å
α=90° β=90.388(8)° γ=90°
Paracetamol pyridine solvate
2(C8H9NO2),C5H5N
CrystEngComm (2015) 17, 39 7543
a=15.5127(13)Å b=8.2524(5)Å c=17.957(2)Å
α=90.00° β=122.004(6)° γ=90.00°
Paracetamol pyridine solvate
2(C8H9NO2),C5H5N
CrystEngComm (2015) 17, 39 7543
a=15.5225(14)Å b=8.2788(5)Å c=17.997(2)Å
α=90.00° β=121.964(7)° γ=90.00°
Paracetamol pyridine solvate
2(C8H9NO2),C5H5N
CrystEngComm (2015) 17, 39 7543
a=15.5367(16)Å b=8.3081(6)Å c=18.051(2)Å
α=90.00° β=121.906(8)° γ=90.00°
Paracetamol pyridine solvate
2(C8H9NO2),C5H5N
CrystEngComm (2015) 17, 39 7543
a=15.5304(15)Å b=8.2953(6)Å c=18.026(2)Å
α=90.00° β=121.942(8)° γ=90.00°
Paracetamol pyridine solvate
2(C8H9NO2),C5H5N
CrystEngComm (2015) 17, 39 7543
a=15.5427(16)Å b=8.3248(6)Å c=18.084(2)Å
α=90.00° β=121.851(8)° γ=90.00°
Paracetamol pyridine solvate
2(C8H9NO2),C5H5N
CrystEngComm (2015) 17, 39 7543
a=15.5533(18)Å b=8.3475(7)Å c=18.151(3)Å
α=90.00° β=121.742(9)° γ=90.00°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.7021(11)Å b=7.1057(8)Å c=9.6760(7)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.804(2)Å b=7.2851(11)Å c=9.6112(14)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.7044(11)Å b=7.1209(8)Å c=9.6716(7)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.815(2)Å b=7.2951(11)Å c=9.6129(13)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.7115(11)Å b=7.1415(8)Å c=9.6639(7)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.832(2)Å b=7.3084(11)Å c=9.6102(14)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.7211(11)Å b=7.1625(8)Å c=9.6562(7)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.841(2)Å b=7.3153(11)Å c=9.6100(13)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.7279(11)Å b=7.1809(8)Å c=9.6504(7)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.7390(11)Å b=7.2001(8)Å c=9.6461(7)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.755(2)Å b=7.2394(11)Å c=9.6181(13)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.736(2)Å b=7.2220(11)Å c=9.6239(13)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.770(2)Å b=7.2540(11)Å c=9.6152(13)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.787(2)Å b=7.2696(11)Å c=9.6113(13)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.881(2)Å b=7.3506(12)Å c=9.6096(14)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.851(2)Å b=7.3236(11)Å c=9.6090(13)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.860(2)Å b=7.3294(11)Å c=9.6098(14)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.872(2)Å b=7.3394(11)Å c=9.6071(14)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.896(3)Å b=7.3587(15)Å c=9.6062(17)Å
α=90° β=90° γ=90°
Disodium 2-amino-6-oxo-6,7-dihydro-1H-purine-1,7-diide heptahydrate
2(Na),7(H2O),C5H3N5O
CrystEngComm (2019) 21, 30 4484
a=10.5380(7)Å b=11.433(7)Å c=10.9920(8)Å
α=90° β=101.824(6)° γ=90°
Tolazamide
C14H21N3O3S
CrystEngComm (2017) 19, 16 2243
a=6.2278(5)Å b=9.026(2)Å c=13.3215(14)Å
α=79.608(13)° β=86.913(8)° γ=85.990(13)°
Glycine-phthalic acid (1:1)
C8H6O4,C2H5NO2
CrystEngComm (2016) 18, 31 5869
a=8.1071(11)Å b=11.3252(12)Å c=23.827(4)Å
α=90° β=90° γ=90°
Glycine-phthalic acid (1:1)
C8H6O4,C2H5NO2
CrystEngComm (2016) 18, 31 5869
a=7.8988(8)Å b=11.3424(12)Å c=23.327(10)Å
α=90° β=90° γ=90°
Glycine-DL-tartaric acid (1:1)
C4H6O6,C2H5NO2
CrystEngComm (2016) 18, 31 5869
a=4.8540(4)Å b=9.3349(11)Å c=19.2555(15)Å
α=98.866(8)° β=92.311(6)° γ=96.887(8)°
Paracetamol pyridine solvate
2(C8H9NO2),C5H5N
CrystEngComm (2015) 17, 39 7543
a=15.5180(14)Å b=8.2664(5)Å c=17.978(2)Å
α=90.00° β=121.982(7)° γ=90.00°
Paracetamol pyridine solvate
2(C8H9NO2),C5H5N
CrystEngComm (2015) 17, 39 7543
a=15.5486(17)Å b=8.3370(7)Å c=18.116(3)Å
α=90.00° β=121.807(8)° γ=90.00°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.825(2)Å b=7.3004(11)Å c=9.6126(14)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-chloride-nitrate
CoH15N6O2,NO3,Cl
CrystEngComm (2016) 18, 38 7276
a=14.877(2)Å b=7.3463(12)Å c=9.6072(14)Å
α=90° β=90° γ=90°
Nitro-pentaammine-Co(III)-dibromide
CoH15N6O2,2(Br)
CrystEngComm (2015) 17, 46 8812
a=10.6807(6)Å b=8.8299(8)Å c=10.9759(5)Å
α=90° β=94.604(5)° γ=90°
Nitro-pentaammine-Co(III)-dibromide
CoH15N6O2,2(Br)
CrystEngComm (2015) 17, 46 8812
a=10.6575(5)Å b=8.7649(9)Å c=10.9567(5)Å
α=90° β=94.589(5)° γ=90°
Nitro-pentaammine-Co(III)-dibromide
CoH15N6O2,2(Br)
CrystEngComm (2015) 17, 46 8812
a=10.6184(4)Å b=8.6082(8)Å c=10.9307(4)Å
α=90° β=94.591(4)° γ=90°
Nitro-pentaammine-Co(III)-dibromide
CoH15N6O2,2(Br)
CrystEngComm (2015) 17, 46 8812
a=10.6792(4)Å b=8.0977(7)Å c=10.9004(4)Å
α=90° β=94.192(4)° γ=90°
Nitro-pentaammine-Co(III)-dibromide
CoH15N6O2,2(Br)
CrystEngComm (2015) 17, 46 8812
a=10.6750(5)Å b=7.8148(8)Å c=10.8204(4)Å
α=90° β=93.829(4)° γ=90°
Nitro-pentaammine-Co(III)-dibromide
CoH15N6O2,2(Br)
CrystEngComm (2015) 17, 46 8812
a=10.6379(4)Å b=7.6361(6)Å c=10.7112(3)Å
α=90° β=93.601(3)° γ=90°
Nitro-pentaammine-Co(III)-dibromide
CoH15N6O2,2(Br)
CrystEngComm (2015) 17, 46 8812
a=10.6148(4)Å b=7.5680(7)Å c=10.6476(4)Å
α=90° β=93.508(3)° γ=90°
Nitro-pentaammine-Co(III)-dibromide
CoH15N6O2,2(Br)
CrystEngComm (2015) 17, 46 8812
a=10.6023(5)Å b=7.5308(7)Å c=10.6049(4)Å
α=90° β=93.439(4)° γ=90°
Nitro-pentaammine-Co(III)-dibromide
CoH15N6O2,2(Br)
CrystEngComm (2015) 17, 46 8812
a=10.5914(5)Å b=7.4435(7)Å c=10.4601(4)Å
α=90° β=93.121(4)° γ=90°
Nitro-pentaammine-Co(III)-dibromide
CoH15N6O2,2(Br)
CrystEngComm (2015) 17, 46 8812
a=10.7595(5)Å b=7.4390(6)Å c=10.0890(4)Å
α=90° β=90° γ=90°
Chlorpropamide
C10H13ClN2O3S
CrystEngComm (2016) 18, 29 5423
a=6.1040(5)Å b=8.9243(8)Å c=12.0304(14)Å
α=90° β=99.516(8)° γ=90°
Tolbutamide form I^H^
C12H18N2O3S
CrystEngComm (2016) 18, 30 5736
a=20.7500(15)Å b=7.9160(7)Å c=9.0580(5)Å
α=90° β=90° γ=90°
Tolbutamide form I^L^
C12H18N2O3S
CrystEngComm (2016) 18, 30 5736
a=20.2133(6)Å b=7.8233(2)Å c=9.0717(2)Å
α=90° β=90° γ=90°
Tolbutamide form I^L^
C12H18N2O3S
CrystEngComm (2016) 18, 30 5736
a=19.7525(3)Å b=7.7998(1)Å c=9.0583(1)Å
α=90° β=90° γ=90°
Tolbutamide form I^L^
C12H18N2O3S
CrystEngComm (2016) 18, 30 5736
a=19.4331(3)Å b=7.8010(1)Å c=9.0277(1)Å
α=90° β=90° γ=90°
Tolbutamide form II
C12H18N2O3S
CrystEngComm (2016) 18, 30 5736
a=9.0256(2)Å b=17.1443(5)Å c=17.7904(5)Å
α=90° β=94.268(3)° γ=90°
N,N-dimethylglycine
C4H9NO2,H2O2
CrystEngComm (2014) 16, 44 10165
a=10.3838(5)Å b=5.7184(3)Å c=11.4118(7)Å
α=90.00° β=90.00° γ=90.00°
N,N,N-hydroxydimethylglycine
C4H9NO3
CrystEngComm (2014) 16, 44 10165
a=5.5044(7)Å b=10.0817(8)Å c=10.2203(13)Å
α=90.00° β=93.142(10)° γ=90.00°
N,N,N-hydroxydimethylglycine
C4H9NO3,O2H2
CrystEngComm (2014) 16, 44 10165
a=12.3320(4)Å b=9.9903(3)Å c=5.80218(16)Å
α=90.00° β=90.00° γ=90.00°
N-methylglycine
C3H7NO2
Physical chemistry chemical physics : PCCP (2015) 17, 5 3534-3543
a=6.7285(4)Å b=7.9107(7)Å c=8.6056(5)Å
α=90.00° β=90.00° γ=90.00°
N-methylglycine
C3H7NO2
Physical chemistry chemical physics : PCCP (2015) 17, 5 3534-3543
a=6.7099(4)Å b=7.9090(7)Å c=8.6098(5)Å
α=90.00° β=90.00° γ=90.00°
N-methylglycine
C3H7NO2
Physical chemistry chemical physics : PCCP (2015) 17, 5 3534-3543
a=6.6925(4)Å b=7.9071(7)Å c=8.6136(5)Å
α=90.00° β=90.00° γ=90.00°
N-methylglycine
C3H7NO2
Physical chemistry chemical physics : PCCP (2015) 17, 5 3534-3543
a=6.6768(4)Å b=7.9039(7)Å c=8.6154(5)Å
α=90.00° β=90.00° γ=90.00°
N-methylglycine
C3H7NO2
Physical chemistry chemical physics : PCCP (2015) 17, 5 3534-3543
a=6.6605(4)Å b=7.9000(7)Å c=8.6170(5)Å
α=90.00° β=90.00° γ=90.00°
N,N,N-trimethylglycine
C5H11NO2
Physical chemistry chemical physics : PCCP (2015) 17, 5 3534-3543
a=14.5561(15)Å b=6.8446(5)Å c=6.1179(5)Å
α=90.00° β=90.00° γ=90.00°
N,N,N-trimethylglycine
C5H11NO2
Physical chemistry chemical physics : PCCP (2015) 17, 5 3534-3543
a=14.5609(16)Å b=6.8598(6)Å c=6.1290(5)Å
α=90.00° β=90.00° γ=90.00°
N,N,N-trimethylglycine
C5H11NO2
Physical chemistry chemical physics : PCCP (2015) 17, 5 3534-3543
a=14.5514(15)Å b=6.8288(5)Å c=6.1066(5)Å
α=90.00° β=90.00° γ=90.00°
N,N,N-trimethylglycine
C5H11NO2
Physical chemistry chemical physics : PCCP (2015) 17, 5 3534-3543
a=14.5449(14)Å b=6.8144(5)Å c=6.0963(4)Å
α=90.00° β=90.00° γ=90.00°
N,N,N-trimethylglycine
C5H11NO2
Physical chemistry chemical physics : PCCP (2015) 17, 5 3534-3543
a=14.5379(13)Å b=6.7879(4)Å c=6.0772(4)Å
α=90.00° β=90.00° γ=90.00°
N,N,N-trimethylglycine
C5H11NO2
Physical chemistry chemical physics : PCCP (2015) 17, 5 3534-3543
a=14.5314(13)Å b=6.7663(4)Å c=6.0577(4)Å
α=90.00° β=90.00° γ=90.00°
Beta-Alanine
C3H7NO2
CrystEngComm (2015) 17, 10 2074
a=9.8829(4)Å b=13.787(7)Å c=6.0816(3)Å
α=90° β=90° γ=90°
Beta-Alanine
C3H7NO2
CrystEngComm (2015) 17, 10 2074
a=9.4310(8)Å b=12.826(16)Å c=5.6952(5)Å
α=90° β=90° γ=90°
Beta-Alanine
C3H7NO2
CrystEngComm (2015) 17, 10 2074
a=5.2593(14)Å b=13.10(4)Å c=4.7408(10)Å
α=90° β=94.32(3)° γ=90°
Beta-Alanine
C3H7NO2
CrystEngComm (2015) 17, 10 2074
a=9.1235(14)Å b=12.78(2)Å c=5.7014(11)Å
α=90° β=90° γ=90°
N-methylglycine
C3H7NO2
Physical chemistry chemical physics : PCCP (2015) 17, 5 3534-3543
a=6.8141(5)Å b=7.9189(8)Å c=8.5887(6)Å
α=90.00° β=90.00° γ=90.00°
N-methylglycine
C3H7NO2
Physical chemistry chemical physics : PCCP (2015) 17, 5 3534-3543
a=6.7737(5)Å b=7.9170(8)Å c=8.5989(5)Å
α=90.00° β=90.00° γ=90.00°
N-methylglycine
C3H7NO2
Physical chemistry chemical physics : PCCP (2015) 17, 5 3534-3543
a=6.7518(4)Å b=7.9135(7)Å c=8.6022(5)Å
α=90.00° β=90.00° γ=90.00°
DL-cysteine
C3H7NO2S
CrystEngComm (2010) 12, 9 2551
a=9.6352(4)Å b=4.9435(2)Å c=12.8853(5)Å
α=90.0° β=121.808(2)° γ=90.0°
DL-cysteine
C3H7NO2S
CrystEngComm (2010) 12, 9 2551
a=9.712(5)Å b=4.9755(20)Å c=13.107(6)Å
α=90.0° β=121.849(25)° γ=90.0°
DL-homocysteine
C4H9NO2S
The journal of physical chemistry. B (2014) 118, 29 8513-8523
a=5.1788(5)Å b=5.4990(5)Å c=11.3501(11)Å
α=102.992(8)° β=91.237(8)° γ=107.058(8)°
Chlorpropamide, α-form
C10H13ClN2O3S
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2013) 69, 1 77
a=26.5733(18)Å b=4.7178(2)Å c=8.6406(2)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, α-form
C10H13ClN2O3S
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2013) 69, 1 77
a=26.573(2)Å b=4.8587(2)Å c=8.8165(4)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, α-form
C10H13ClN2O3S
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2013) 69, 1 77
a=26.605(2)Å b=4.6688(2)Å c=8.5711(3)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, α-form
C10H13ClN2O3S
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2013) 69, 1 77
a=26.6068(19)Å b=4.6576(2)Å c=8.5556(2)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, α^II^-form
C10H13ClN2O3S
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2013) 69, 1 77
a=25.602(3)Å b=4.6340(2)Å c=8.8525(4)Å
α=99.109(4)° β=90.00° γ=90.00°
Chlorpropamide, α^II^-form
C10H13ClN2O3S
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2013) 69, 1 77
a=25.522(6)Å b=4.6023(7)Å c=8.8298(15)Å
α=99.477(14)° β=90.00° γ=90.00°
Metacetamol hemihydrate
2(C8H9NO2),H2O
Acta Crystallographica Section C (2019) 75, 11
a=12.7626(4)Å b=6.92827(14)Å c=19.7011(4)Å
α=90° β=104.619(3)° γ=90°
Bis(<i>L</i>-cysteinium) <i>L</i>-cysteine difluoride hydrogen fluoride
2(C3H8N1O2S1),2(F),C3H7NO2S,HF
Acta Crystallographica Section C (2015) 71, 8
a=11.8730(6)Å b=5.2291(2)Å c=15.3459(9)Å
α=90.00° β=106.602(4)° γ=90.00°
Furosemide <i>N</i>,<i>N</i>-dimethylacetamide disolvate
C12H11ClN2O5S,2(C4H9NO)
Acta Crystallographica Section C (2016) 72, 12 997-1001
a=17.0284(10)Å b=7.8695(3)Å c=22.0555(15)Å
α=90° β=126.512(4)° γ=90°
2(C15H13N3O4S),C4H6O4
2(C15H13N3O4S),C4H6O4
Acta Crystallographica Section C (2019) 75, 1 29-37
a=7.6779(9)Å b=8.4177(9)Å c=14.3934(10)Å
α=79.528(8)° β=74.650(8)° γ=72.820(10)°
Piroxicam--succinic acid--acetonitrile (4/1/2)
4(C15H13N3O4S),C4H6O4,2(C2H3N)
Acta Crystallographica Section C (2019) 75, 1 29-37
a=9.1561(3)Å b=12.7660(5)Å c=15.1022(5)Å
α=83.030(3)° β=75.313(3)° γ=83.972(3)°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.3453(3)Å b=9.1929(5)Å c=13.4917(7)Å
α=79.103(5)° β=87.266(4)° γ=85.857(5)°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.3506(6)Å b=9.2241(9)Å c=13.4984(13)Å
α=79.091(8)° β=87.215(8)° γ=85.815(8)°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.3346(3)Å b=9.1641(5)Å c=13.4642(7)Å
α=79.222(4)° β=87.305(4)° γ=85.936(4)°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.3186(5)Å b=9.1502(8)Å c=13.4244(11)Å
α=79.314(7)° β=87.303(7)° γ=85.948(7)°